NCT05471674View on ClinicalTrials.gov

Neoadjuvant Anti-PD1 in HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Hepatocellular CarcinomaHCCLiver Cancer
Interventions
DRUG

Nivolumab

3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses

PROCEDURE

Hepatectomy

Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Dr Tan-to CHEUNG

OTHER

NCT05471674 - Neoadjuvant Anti-PD1 in HCC | Biotech Hunter | Biotech Hunter